<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Iran Med</journal-id><journal-id journal-id-type="iso-abbrev">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">AIM</journal-id><journal-title-group><journal-title>Archives of Iranian Medicine</journal-title></journal-title-group><issn pub-type="ppub">1029-2977</issn><issn pub-type="epub">1735-3947</issn><issn-l>1029-2977</issn-l><publisher><publisher-name>Academy of Medical Sciences of I.R. Iran</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891455</article-id><article-id pub-id-type="pmc">PMC11786208</article-id><article-id pub-id-type="doi">10.34172/aim.31710</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Radiological Findings for Distinguishing Between Xanthogranulomatous Cholecystitis and Gallbladder Cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0467-741X</contrib-id><name><surname>Bozer</surname><given-names>Ahmet</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-6159-6569</contrib-id><name><surname>Durgun</surname><given-names>Nagihan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="A01">
<sup>1</sup>Department of Radiology, Izmir City Hospital, Izmir, Turkey</aff><author-notes><corresp id="COR1">
<label>*</label><bold>Corresponding Author:</bold> Ahmet Bozer, Email: <email>drahmetbozer@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>12</month><year>2024</year></pub-date><volume>27</volume><issue>12</issue><fpage>674</fpage><lpage>682</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Author(s).</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="https://journalaim.com">https://journalaim.com</self-uri><abstract><sec id="sa1"><title>Background:</title><p> Xanthogranulomatous cholecystitis (XGC) is a rare, chronic gallbladder inflammation often mistaken for gallbladder cancer (GBC) on imaging. Accurate differentiation is vital for appropriate treatment. This study aims to enhance computed tomography (CT) scan diagnostic accuracy for distinguishing XGC from GBC.</p></sec><sec id="sa2"><title>Methods:</title><p> This retrospective study included patients diagnosed with XGC and GBC between 2014 and 2023. CT images of 70 patients (16 GBC, 54 XGC) were reviewed. Radiologists assessed CT parameters: gallbladder wall thickening, intramural hypoattenuating nodules, enhancement characteristics, mucosal line continuity, pericholecystic fat stranding, presence of stones, bile duct dilatation, hepatic invasion, invasion to adjacent structures, and lymph node size.</p></sec><sec id="sa3"><title>Results:</title><p> Among 70 patients, there were 38 males (54%) and 32 females (46%), with a median age of 62 years. GBC patients were significantly older (median age 72 years) compared to XGC patients (60 years) (<italic toggle="yes">P</italic>=0.001). Diffuse gallbladder wall thickening was more frequent in XGC (70%) than GBC (12.5%) (<italic toggle="yes">P</italic>&#x0003c;0.001). Continuous mucosal lines and intramural hypoattenuating nodules were more common in XGC (<italic toggle="yes">P</italic>&#x0003c;0.001 and <italic toggle="yes">P</italic>=0.010, respectively). Intrahepatic bile duct dilatation and invasion to adjacent structures were significantly linked with GBC (<italic toggle="yes">P</italic>&#x0003c;0.001 and <italic toggle="yes">P</italic>=0.043). Lymph nodes with a short axis&#x0003e;8 mm indicated GBC (<italic toggle="yes">P</italic>&#x0003c;0.001), with a cutoff providing 71.4% sensitivity and 84% specificity (AUC: 0.843, <italic toggle="yes">P</italic>&#x0003c;0.001). CT showed 75% sensitivity (95% CI: 48-93%), 74% specificity (95% CI: 60%-85%), and 74% accuracy (95% CI: 62%-84%).</p></sec><sec id="sa4"><title>Conclusion:</title><p> CT imaging can effectively differentiate XGC from GBC, and larger studies can further improve diagnostic accuracy.</p></sec></abstract><kwd-group><kwd>Computed tomography</kwd><kwd>Differential diagnosis</kwd><kwd>Gallbladder cancer</kwd><kwd>Radiology</kwd><kwd>Xanthogranulomatous cholecystitis</kwd></kwd-group></article-meta><notes><p>
<bold>Cite this article as:</bold> Bozer A, Durgun N. Radiological findings for distinguishing between xanthogranulomatous cholecystitis and gallbladder cancer. Arch Iran Med. 2024;27(12):674-682. doi: 10.34172/aim.31710</p></notes></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p> Xanthogranulomatous cholecystitis (XGC) stands out as an uncommon type of chronic cholecystitis marked by inflammation within the gallbladder, accompanied by infiltration of both acute and chronic inflammatory cells.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> A defining feature of this condition is the accumulation of lipid-laden macrophages within the gallbladder wall.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Consequently, XGC frequently results in substantial adhesions between the gallbladder and neighboring structures such as the duodenum, colon, and stomach. This inflammatory process can mimic gallbladder cancer (GBC), posing diagnostic challenges for both clinicians and radiologists.</p><p> XGC is an uncommon condition, with a prevalence estimated to be between 0.7% and 10%.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> While GBC, which shares similar clinical and radiological features with XGC, is infrequent, based on the GLOBOCAN 2018 data, GBC represents only 1.2% of all global cancer diagnoses but accounts for 1.7% of all cancer-related fatalities. It is frequently identified at an advanced stage, with an average survival of less than one year for advanced-stage cancer.<sup><xref rid="R4" ref-type="bibr">4</xref></sup></p><p> In both of these rare diseases, patients present with similar symptoms such as pain, obstructive jaundice, cholangitis, and a palpable mass. Distinguishing between these two conditions through laboratory tests is quite challenging. Although elevated tumor markers are observed in XGC, it can often lead to concerns among surgeons due to the potential confusion with GBC.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Therefore, the commonly detected high levels of CA19-9 in XGC may not reliably differentiate malignancy. The increase in CA19-9 can be attributed to the epithelial cell damage in the gallbladder wall and bile ducts caused by inflammation, particularly in obstructive cases. Hence, preoperative radiological findings play a crucial role in the diagnostic challenge posed by these two gallbladder pathologies.</p><p> Studies have investigated the use of diagnostic tools such as contrast-enhanced ultrasound (CEUS), diffusion-weighted imaging (DWI) added to conventional and multiparametric magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET/CT), alongside standard modalities like ultrasound (US), computed tomography (CT), and MRI, in the preoperative differentiation of benign and malignant gallbladder lesions.<sup><xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R9" ref-type="bibr">9</xref></sup> In one study, Lee et al<sup><xref rid="R10" ref-type="bibr">10</xref></sup> found MRI to be superior to CT and US among conventional diagnostic tools in differentiating XGC from gallbladder carcinoma. Bo et al<sup><xref rid="R11" ref-type="bibr">11</xref></sup> reported that CEUS demonstrated the highest diagnostic performance, followed by abdominal US, MRI, CT, and PET/CT. Similarly, Sabat&#x000e9;-Llobera et al<sup><xref rid="R12" ref-type="bibr">12</xref></sup> found PET/CT to have comparable accuracy to conventional imaging techniques in distinguishing between benign and malignant gallbladder lesions. In light of these findings, the diagnostic performance and superiority of different modalities remain inconclusive.</p><p> This research seeks to enhance the accuracy of CT, a pivotal radiological tool, in differentiating between XGC and GBC. By identifying and analyzing distinct imaging features, it aims to improve the accuracy of preoperative diagnoses, thereby aiding in the effective clinical management of these rare pathologies. Our research will explore the diagnostic capabilities of CT and propose specific criteria that can enhance its utility in clinical settings. The findings aim to provide radiologists and clinicians with better tools to distinguish between XGC and GBC and make informed decisions regarding patient care.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><sec sec-type="subsection" id="s2-1"><title> Patient Selection</title><p> Our study was designed retrospectively following approval from the ethics committee (approval number: 2023/196, dated 15.11.2023). Patients diagnosed with XGC and GBC between 2014 and 2023 were included in our study. During the specified years, 35 patients were diagnosed with GBC, while 92 patients were confirmed to have XGC.</p><p> The exclusion criteria were as follows: absence of adequate imaging in our hospital&#x02019;s CT scan protocol (27 patients), presence of only non-contrast images due to various reasons (10 patients), images being too artifact-laden for evaluation (8 patients), history of malignancy other than GBC (4 patients), inadequate medical records (7 patients), and diagnosis of both XGC and GBC (1 patient). Eventually, 16 patients remained in the GBC group, while 54 patients remained in the XGC group.</p></sec><sec sec-type="subsection" id="s2-2"><title> Imaging Technique</title><p> Dynamic imaging was performed on patients included in our study using the Siemens SOMATOM Definition AS 64 CT scanner. The protocol consisted of 128 slices with a collimation of 0.625 and a slice thickness of 5 mm. The pitch was set to 0.9 with a rotation time of 0.5 seconds at 120 kVp and 150-200 mAs.</p><p> A non-ionic contrast agent (Ultravist 370 mg iodine/mL, Berlin, Germany) was administered at a rate of 1-2 mL/kg using an automatic injector at a speed of 3-4 mL/s. Imaging was conducted at 30 seconds post-contrast for the arterial phase and 60 seconds post-contrast for the portovenous phase.</p></sec><sec sec-type="subsection" id="s2-3"><title> Imaging Interpretation</title><p> All images were evaluated by two radiologists with 9 and 4 years of experience in abdominal radiology, who reached a consensus. In cases where a decision could not be reached, our abdominal radiologist with 30 years of experience provided guidance.</p><p> The following parameters were evaluated in the patients&#x02019; images:</p><list list-type="bullet"><list-item><p>Presence of gallbladder wall thickening, including thickness (mm), and wall thickness pattern (focal, diffuse, polypoid, massive), </p></list-item><list-item><p>Assessment of the presence of intramural hypoattenuating nodules in the thickened wall, </p></list-item><list-item><p>Evaluation of enhancement characteristics of the gallbladder wall (homogeneous or heterogeneous), </p></list-item><list-item><p>Examination of continuity of mucosal lines (continuous or disrupted), </p></list-item><list-item><p>Presence of pericholecystic fat stranding and infiltration, </p></list-item><list-item><p>Assessment of stones in the gallbladder and bile ducts, </p></list-item><list-item><p>Examination of intra-extrahepatic bile duct dilatation, </p></list-item><list-item><p>Assessment of macroscopic hepatic invasion and extent, </p></list-item><list-item><p>Assessment of invasion to adjacent structures (duodenum, hepatic flexure of the colon), </p></list-item><list-item><p>Finally, the presence of regional lymph nodes was assessed. If present, the short-axis dimension of the lymph node was measured. Additionally, a separate assessment was conducted to identify lymph nodes with a short-axis dimension greater than 10 mm (<xref rid="F1" ref-type="fig">Figures 1</xref>-<xref rid="F3" ref-type="fig">3</xref>). </p></list-item></list><fig position="float" id="F1"><label>Figure 1</label><graphic xlink:href="aim-27-674-g001" position="float"/><statement><p>
Computed Tomography Images of Four Patients with Histopathologically Confirmed Xanthogranulomatous Cholecystitis. Axial (a) and sagittal (b) images from patient 1; axial (c) and sagittal (d) images from patient 2; axial images (e, f) from patient 3; and axial images (g, h) from patient 4. The images illustrate findings such as diffuse gallbladder wall thickening (white arrow), continuity of the mucosal line (black arrowhead), intramural hypodense nodules (white arrowhead), pericholecystic infiltration (asterisk), and an indistinct interface suggesting infiltration into the liver parenchyma (black arrow)</p></statement></fig><fig position="float" id="F2"><label>Figure 2</label><graphic xlink:href="aim-27-674-g002" position="float"/><statement><p>
Computed Tomography Images of a Histopathologically Diagnosed Case of Xanthogranulomatous Cholecystitis Preoperatively Misdiagnosed as Gallbladder Carcinoma. Axial (a, b), sagittal (c), and coronal (d) post-contrast portal venous phase CT images show a collapsed gallbladder with asymmetrical wall thickening and a mass-like appearance (arrow), and minimal pericholecystic fat stranding (arrowhead). No regional lymph node enlargement or invasion to the liver and adjacent structures is observed. However, characteristic features suggestive of XGC, such as intramural hypodense nodules and continuity of the mucosal line, are not present</p></statement></fig><fig position="float" id="F3"><label>Figure 3</label><graphic xlink:href="aim-27-674-g003" position="float"/><statement><p>
Computed Tomography Images of Four Cases Histopathologically Diagnosed with Gallbladder Carcinoma. (a) Shows a mass lesion (arrow) originating from the gallbladder wall with polypoid extension into the lumen and invasion into the adjacent liver parenchyma (arrowhead). (b) Demonstrates focal thickening of the gallbladder (arrow) and disrupted mucosal line (arrowhead). (c) Displays asymmetrical wall thickening (arrow) and intrahepatic bile duct dilatation (arrowhead). (d) Reveals focal concentric thickening of the gallbladder wall (arrow)</p></statement></fig></sec><sec sec-type="subsection" id="s2-4"><title> Statistical Analysis </title><p> Analysis of the data obtained in the study was conducted using IBM SPSS Statistics 26 (IBM Corp., Armonk, NY, USA). The suitability of continuous variables for normal distribution was assessed through graphical evaluation, normality tests, and sample size analysis, showing that they did not meet the conditions of normal distribution. Continuous variables were presented as median and interquartile range (IQR) (25-75). The Mann-Whitney U test was used for comparisons between independent groups. ROC analysis was performed to determine the diagnostic power of the parameters, and the optimal cut-off value was identified using Youden&#x02019;s J index. Categorical variables were presented as frequencies and percentages in cross-tables, with comparisons conducted using the chi-square and Fisher&#x02019;s Exact tests. For dependent categorical variables, the McNemar test was applied, and predictive values were calculated. All statistical tests were two-tailed with a type one error margin set at &#x003b1;: 0.05.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p> Our study included 70 patients, of whom 38 (54%) were male and 32 (46%) female. The median age was 62 years (IQR: 51-72).</p><p> In the GBC group, the median age (IQR) was found to be 72 years (64-78), while in the XGC group, it was 60 (49-68). The GBC group had a higher average age, and the difference in age between the two groups was statistically significant (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.001) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Comparative Patient Demographics and Radiological Features of Gallbladder Carcinoma and Xanthogranulomatous Cholecystitis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="3" colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;">
<bold>Features</bold>
</td><td rowspan="3" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<bold>Total</bold>
<break/>
<bold>N (%)</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Pathological Diagnosis</bold>
</td><td rowspan="3" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold> Value </bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>GBC</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>XGC</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N (%)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N (%)</bold>
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">Gender</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Male</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">38 (54%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">7 (44%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">31 (57%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">0.498*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Female</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (46%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (56%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23 (43%)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Age, Med.(IQR)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">62 (51-72)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">72 (64-78)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">60 (49-68)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.001**</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Wall thickness (mm), Med. (IQR)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (4-7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (3-9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (4-6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.428**</td></tr><tr><td rowspan="4" style="text-align:left;vertical-align:middle;" colspan="1">Gallbladder wall thickening pattern</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Focal</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">24 (34%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (30%)</td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">N/A</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Diffuse</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">40 (57%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (12.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">38 (70%)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Polypoid</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (25%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Massive</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (3%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (12.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0%)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Focal gallbladder wall thickening </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">24 (34%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (30%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.227</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">46 (66%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">38 (70%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Diffuse gallbladder wall thickening </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">40 (57%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (12.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">38 (70%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">&#x02005;&#x0003c;&#x02005;0.001*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (43%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (87.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (30%)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Enhancement characteristics of gallbladder wall</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Homogeneous</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">43 (61%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (56%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">34 (63%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.848*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Heterogeneous</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (39%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (44%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">20 (37%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Continuity of mucosal line</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Continuous</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">44 (63%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (6%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">43 (80%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">&#x02005;&#x0003c;&#x02005;0.001*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Disrupted</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">26 (37%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (94%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (20%)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Pericholecystic fat stranding</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">56 (80%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (87.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">42 (78%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.497*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (20%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (12.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (22%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Pericholecystic infiltratio </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">41 (59%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">33 (61%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.615*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">29 (41%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21 (39%)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Intramural hypoattenuating nodules in the thickened wall</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">35 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (19%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (59%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.010*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">35 (50%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (81%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (41%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Stones (gallbladder and bile ducts)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">42 (60%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (63%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (59%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">1.000*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">28 (40%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (37%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (41%)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Intrahepatic bile duct dilatation</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18 (26%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (75%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (11%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">&#x02005;&#x0003c;&#x02005;0.001*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">52 (74%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (25%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">48 (89%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Extra-hepatic bile duct dilatation</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (23%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (37%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (19%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.172*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (77%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (63%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">44 (81%)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Macroscopic hepatic invasion</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (23%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (37%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (19%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.172*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (77%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (63%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">44 (81%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">Macroscopic hepatic invasion extent</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Indistinct border</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (16%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (25%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (13%)</td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">N/A</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Massive</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (7%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (12.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (6%)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">None</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (77%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (62.5%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">44 (81%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Invasion to adjacent structures (duodenum, hepatic flexure of the colon)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (10%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (25%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (6%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.043*</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">63 (90%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12 (75%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">51 (94%)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">LN (regardless of size)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (46%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (44%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">25 (46%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">1.000*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">38 (54%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (56%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">29 (54%)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">LN short axis dimension (mm), Med.(IQR)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (5-9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (7-11)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (5-7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.006**</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">LN short axis dimension (cut-off value)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003e;&#x02005;8 mm</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9(28%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5(71%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4(16%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.010*</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x02264;&#x02005;8 mm</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23(72%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2(29%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21(84%)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">LN (short axis&#x02005;&#x0003e;&#x02005;10 mm)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Present</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (9%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (25%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (4%)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.022*</td></tr><tr><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Absent</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">64 (91%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">12 (75%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">52 (96%)</td></tr></tbody></table><table-wrap-foot><fn><p> Med: Median, IQR: Interquantile range (25-75), N/A: Not available, LN: Lymph node; GBC: Gallbladder carcinoma; XGC: Xanthogranulomatous cholecystitis.</p><p>
<sup>*</sup>Pearson chi-square test or Fisher&#x02019;s exact test, <sup>**</sup>Mann-Whitney U test.</p></fn></table-wrap-foot></table-wrap><p> The distribution of gallbladder wall thickening patterns among the groups is presented in <xref rid="T1" ref-type="table">Table 1</xref>. Diffuse gallbladder wall thickening was observed in 2 patients (12.5%) in the GBC group and in 38 patients (70%) in the XGC group. This difference was found to be statistically significant (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001). The presence of focal gallbladder wall thickening was not significantly different between the two groups (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.227).</p><p> A continuous mucosal line was observed in 1 patient (6%) in the GBC group and in 43 patients (80%) in the XGC group. This difference was statistically significant (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001).</p><p> Additionally, intramural hypoattenuating nodules in the thickened wall were observed in 3 patients (19%) in the GBC group and in 32 patients (59%) in the XGC group, with this difference being statistically significant (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.010).</p><p> Among the parameters examined on CT, intrahepatic bile duct dilatation was present in 75% (n:12) of GBC patients and in 11% (n:6) of XGC patients. This difference between the two groups was statistically significant (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001).</p><p> Invasion to adjacent structures (duodenum, hepatic flexure of the colon) was present in 25% (n:4) of GBC patients and in 6% (n:3) of XGC patients. This parameter was found to be statistically significant between the two groups (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.043, <xref rid="T1" ref-type="table">Table 1</xref>).</p><p> The median (IQR) of lymph node short axis dimension was found to be 11 (7-11) in the GBC group and 6 (5-7) in the XGC group, with statistical significance (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.006) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p> To determine a cut-off value for the short axis of lymph nodes that can distinguish between the two groups, ROC analysis was conducted. A cut-off value of 8 mm was found with 71.4% sensitivity, 84% specificity, and an AUC of 0.843 (<italic toggle="yes">P</italic>&#x0003c;&#x02005;0.001) (<xref rid="F4" ref-type="fig">Figure 4</xref>). At this cut-off value, the distribution of lymph nodes in both groups is shown in <xref rid="T1" ref-type="table">Table 1</xref> (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.010).</p><fig position="float" id="F4"><label>Figure 4</label><graphic xlink:href="aim-27-674-g004" position="float"/><statement><p>
ROC Analysis for Determining the Cut-off Value for the Short Axis Dimension of Lymph Nodes</p></statement></fig><p> Other parameters examined on CT showed no statistically significant distinctions between the two groups (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p> The diagnostic performance of CT in distinguishing between GBC and XGC groups showed a sensitivity of 75% (95% CI: 48%-93%), a specificity of 74% (95% CI: 60%-85%), and an accuracy of 74% (95% CI: 62%-84%) (<xref rid="T2" ref-type="table">Table 2</xref>, <xref rid="F5" ref-type="fig">Figure 5</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><title>Diagnostic Performance of Computed Tomography for Gallbladder Carcinoma and Xanthogranulomatous Cholecystitis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Value</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>95% CI</bold>
</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Sensitivity</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">75%</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">48% to 93%</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Specificity</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">74%</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">60% to 85%</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">AUC</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.75</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.63 to 0.84</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Positive Likelihood Ratio</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.89</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.70 to 4.93</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Negative Likelihood Ratio</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.34</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.14 to 0.80</td></tr><tr><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Positive Predictive Value</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">46%</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">33% to 59%</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Negative Predictive Value</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">91%</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">81% to 96%</td></tr><tr><td style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Accuracy</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">74%</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">62% to 84%</td></tr></tbody></table></table-wrap><fig position="float" id="F5"><label>Figure 5</label><graphic xlink:href="aim-27-674-g005" position="float"/><statement><p>
Schematic Comparison of Radiological and Pathological Diagnoses for Gallbladder Carcinoma (GBC) and Xanthogranulomatous Cholecystitis (XGC)</p></statement></fig><p> The concordance between radiological and pathological diagnoses of GBC and XGC reveals that out of the 70 total cases, radiological diagnosis correctly identified 12 cases of GBC (17.1%) and 40 cases of XGC (57.1%). However, it misclassified 4 cases of GBC as XGC (5.7%) and 14 cases of XGC as GBC (20.0%) (<xref rid="T3" ref-type="table">Table 3</xref>). The McNemar test indicated a statistically significant difference (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.031), with a difference in diagnostic accuracy of 14.3% (95% CI: 2.9% to 25.7%) (<xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><title>Concordance between Radiological and Pathological Diagnoses of Gallbladder Carcinoma and Xanthogranulomatous Cholecystitis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="3" colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;">
</td><td colspan="4" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Pathological Diagnosis</bold>
</td><td rowspan="2" colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;">
<bold>Total </bold>
</td></tr><tr><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>GBC</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>XGC</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>(Tot.) %</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>(Tot.) %</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>N</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>(Tot.) %</bold>
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">Radiological diagnosis</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">GBC</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">12</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">17.1 </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">14</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">20.0 </td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">26</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">37.1</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">XGC</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.7 </td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">40</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">57.1</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">44</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">62.9</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">Total</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">16</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">22.9 </td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">54</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">77.1</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">70</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">100.0</td></tr></tbody></table><table-wrap-foot><fn><p> GBC: Gallbladder carcinoma; XGC: Xanthogranulomatous cholecystitis.</p><p> McNemar test <italic toggle="yes">P</italic> value: 0.031<sub>, </sub>Difference (95% CI): 14.3% (2.9 to 25.7).</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p> Preoperative differentiation between XGC and GBC based on clinical, laboratory, and radiological findings can be challenging. However, it is vital to make this distinction. Misdiagnosis can result in inappropriate surgical interventions, like opting for a radical cholecystectomy and organ resection for XGC or a simple laparoscopic cholecystectomy for suspected malignancies. Although ultrasound-guided fine-needle aspiration (FNA) has been attempted preoperatively, a negative FNA does not exclude GBC, if the sampled area does not represent the lesion.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> Some studies have recommended ultrasound-guided FNA in cases of focal or diffuse gallbladder wall thickening. However, due to operator dependency and the associated risks of tumor dissemination and fistula formation, it is not used routinely.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p><p> Intraoperative frozen section is regarded as the gold standard for distinguishing between these two conditions, despite concerns regarding time and cost.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> However, due to the resemblance between XGC and GBC, radical surgery, including organ resection, might still be performed in XGC cases, leading to high morbidity and mortality. Therefore, while preoperative radiological differentiation between XGC and GBC is important, it remains challenging. Accurate radiological assessment can help guide the surgical approach, potentially avoiding inappropriate surgery and improving patient management, though limitations in imaging must be acknowledged.</p><p> GBC typically manifests after the age of 60 due to the prolonged development of malignancy over many years.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Similarly, XGC tends to occur in older adults.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> However, in our study, the median age of the GBC group was higher than that of the XGC group, and the age distribution between the two groups was found to be statistically significant. In the literature, some studies have found no statistically significant difference in age between these two groups.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> However, Rajaguru et al, in their scoring system developed to distinguish between the two groups, found that age above 55 was a significant factor for GBC, while an age below 55 was significant for XGC.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p><p> Diffuse gallbladder wall thickening, continuity of the mucosal line, and intramural hypoattenuating nodules in the thickened wall were found to be significant for XGC. There is sufficient literature suggesting that these radiological features are diagnostic for XGC.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R22" ref-type="bibr">22</xref>-<xref rid="R24" ref-type="bibr">24</xref></sup> However, as observed in our study, these features can also be occasionally present in the GBC group.</p><p> In our study, absence of intrahepatic bile duct dilatation (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001), absence of invasion to adjacent structures (duodenum, hepatic flexure of the colon) (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.043), and short axis of regional lymph nodes less than 8 mm (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.010) were also found to be significant for XGC. However, there are studies in the literature indicating that intrahepatic bile duct dilatation is not significant in distinguishing between the two groups.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> In XGC cases, severe inflammation and adhesions can lead to bile duct dilatation due to compressive effects in the chronic phase.</p><p> In our study, macroscopic hepatic invasion was observed in 6 patients (37%) in the GBC group and 10 patients (19%) in the XGC group, with no significant difference between the groups (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.172). Although the absence of macroscopic hepatic invasion suggests XGC, pseudo-tumoral presentations of XGC can exhibit extension to adjacent organs and structures.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> Additionally, invasion to adjacent structures (duodenum, hepatic flexure of the colon) was found to be statistically significant between the two groups.</p><p> The median measurement of the short axis of regional lymph nodes was found to be statistically significant between the two groups. Subsequently, a cutoff value of 8 mm for the short axis of regional lymph nodes was calculated to distinguish between the two groups. This means that a short axis measurement of regional lymph nodes above 8 mm suggests GBC, while measurements equal to or below 8 mm suggest XGC (71.4% sensitivity, 84% specificity). Additionally, our study found that lymph nodes with a short axis greater than 10 mm were statistically significant between the two groups (<italic toggle="yes">P</italic>&#x02005;=&#x02005;0.022) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p> Consistent with our study, some previous research has demonstrated that enlarged lymph nodes can be used to distinguish between the two groups.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> In a cohort study comprising 60 cases, Wasnik et al<sup><xref rid="R26" ref-type="bibr">26</xref></sup> identified a correlation between lymph node size and the likelihood of malignancy when distinguishing GBC from acute cholecystitis and XGC. However, there are also studies in the literature that have found enlarged lymph nodes in the XGC group, concluding that they cannot be used to differentiate from GBC.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup></p><p> GBC lymph node metastasis is one of the most common types of metastasis and is the most important factor affecting the clinical staging of GBC. A lymph node with a diameter greater than 1 cm detected by imaging methods is considered a positive criterion for lymph node metastasis.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> The 1-cm value here is used for metastatic involvement. However, the cut-off value we found in our study, which is 8 mm, can be used with high sensitivity and specificity to differentiate between the XGC and GBC groups. Except for our study, there is no research in the literature that determines the cutoff value for lymph node short-axis measurement to differentiate between XGC and GBC.</p><p> In our study, stones (gallbladder and bile ducts) were present in 63% (10 out of 16) of GBC cases and 59% (32 out of 54) of XGC cases. The presence of stones in the gallbladder and bile ducts was not found to be statistically significant in differentiating between the two groups. Cholelithiasis, due to chronic irritation of the mucosa, leads to mucosal metaplasia, dysplasia, and subsequently carcinoma, and is a well-known risk factor for GBC.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Approximately 95% of GBCs are associated with gallstones.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Similarly, the most significant association with XGC is gallstones, observed in approximately 80% of cases.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> These findings suggest that using the presence of gallstones to differentiate between the two groups may not be appropriate. However, some studies have found a higher prevalence of gallbladder stones in the XGC group compared to GBC, with statistical significance.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup></p><p> In our study, CT demonstrated reasonable diagnostic performance in distinguishing between GBC and XGC, with a sensitivity of 75%, specificity of 74%, and accuracy of 74% (<xref rid="T2" ref-type="table">Table 2</xref>). However, 14 out of 54 XGC patients were falsely reported as GBC on CT, and 4 out of 16 GBC patients were interpreted as false negatives on CT (<xref rid="T3" ref-type="table">Table 3</xref>). Similar findings have been reported in previous studies.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> This underscores the diagnostic challenge and variability in distinguishing between GBC and XGC using CT alone, as shown in <xref rid="T3" ref-type="table">Table 3</xref>.</p><p> In a study involving 88 patients, Lee et al<sup><xref rid="R10" ref-type="bibr">10</xref></sup> compared the diagnostic performance of high-resolution ultrasound (HRUS), CT, and MRI in differentiating between XGC and GBC. Despite MRI demonstrating superior performance to both HRUS and CT, HRUS exhibited better performance than CT.</p><p> In another study, Bo et al<sup><xref rid="R11" ref-type="bibr">11</xref></sup> found that CEUS exhibited superior diagnostic performance, with a sensitivity and specificity of 90% and 93%, respectively, compared to other imaging modalities including abdominal US, CT, MRI, and PET/CT, in distinguishing between XGC and GBC. They reported sensitivity and specificity values of 71% and 92%, respectively, for CT.</p><p> Kalage et al<sup><xref rid="R8" ref-type="bibr">8</xref></sup> conducted a study to investigate the diagnostic performance of a multiparametric MRI protocol for characterizing gallbladder wall thickening. They utilized a combination of DWI, intravoxel incoherent motion, diffusion tensor imaging, and dynamic contrast-enhanced MRI (DCE-MRI). Their findings demonstrated that the multiparametric protocol significantly enhanced the sensitivity (90%) and specificity (88%) for distinguishing malignant gallbladder wall thickening from benign cases, with quantitative parameters such as time to peak enhancement and mean diffusivity showing strong associations with malignancy.</p><p> Han et al<sup><xref rid="R31" ref-type="bibr">31</xref></sup> developed an MRI scoring system to differentiate XGC from GBC, achieving excellent diagnostic performance with an AUC of 0.972. This MRI scoring system incorporated nine features: diffuse gallbladder wall thickening, mucosal uniformity, intramural T2-high signal intensity, mucosal retraction, gallbladder stones, T1-intermediate to high-signal intensity, diffusion restriction, enhancement pattern, and phase of peak enhancement. Although there are studies supporting the diagnosis of XGC through the identification of intramural foamy histiocyte accumulation and fat content using the chemical shift artifact, which shows higher signal intensity on in-phase images compared to opposed-phase images,<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> Han et al<sup><xref rid="R31" ref-type="bibr">31</xref></sup> observed this phenomenon in only five patients (8%) in their XGC cohort. Therefore, they concluded that it should not be considered a reliable indicator of intramural fat content.</p><p> In contrast, Ito et al<sup><xref rid="R19" ref-type="bibr">19</xref></sup> developed a CT scoring system based on five CT features: diffuse wall thickening, absence of polypoid lesions, intramural nodules or bands, pericholecystic infiltration, and pericholecystic abscess. By applying three or more of these features, they achieved a sensitivity of 77% (95% CI: 57%-87%) and a specificity of 94% (95% CI 86%-98%) in distinguishing XGC from GBC. The AUC of the MRI scoring system developed by Han et al<sup><xref rid="R31" ref-type="bibr">31</xref></sup> was slightly higher than that of the CT scoring system proposed by Ito et al.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> In our study, we identified CT features such as absence of intrahepatic bile duct dilatation, lack of invasion to adjacent structures, and smaller regional lymph nodes (less than 8 mm), which could be incorporated into the existing scoring systems to further improve diagnostic accuracy in differentiating the two groups.</p><p> In light of these findings, our study underscores the significance of refining diagnostic approaches by integrating additional radiological features to enhance accuracy. Incorporation of the CT features identified in our study could contribute to more accurate preoperative differentiation between XGC and GBC, thereby supporting improved clinical decision-making and ultimately leading to better patient outcomes. This approach can guide more tailored treatment strategies, minimize unnecessary procedures, and optimize patient care.</p><p> Variations in patient characteristics, including age, ethnicity, and regional healthcare access, may influence diagnostic patterns and treatment outcomes. Future multicenter studies, incorporating diverse populations from different geographic regions, would enhance the generalizability of our findings, providing a more comprehensive understanding of the clinical implications across varied settings and improving the external validity of our conclusions.</p><p> One of the study&#x02019;s limitations is its retrospective design, which could introduce selection bias and constrain the generalizability of the results. Additionally, the relatively small sample size, particularly in the GBC group, may affect the statistical power of the analysis. Lastly, the single-center nature of the study may limit the external validity of the results and necessitate further validation in larger, multicenter cohorts to confirm the generalizability of the identified radiological findings. The patient population in this study had a relatively high average age, which, along with factors such as motion artifacts, may have limited the acquisition of optimal imaging quality. Additionally, comorbidities and contraindications, such as impaired renal function limiting the use of contrast agents, led to further exclusions from the study. A strict exclusion criterion was applied to ensure the homogeneity of the study population and minimize the potential impact of these factors on the results.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p> In conclusion, differentiation between XGC and GBC remains a challenging task due to their overlapping clinical and radiological features. Our findings highlight that specific radiological parameters, such as diffuse gallbladder wall thickening, the continuity of the mucosal line, and the presence of intramural hypoattenuating nodules, are significantly associated with XGC. Furthermore, absence of intrahepatic bile duct dilatation, lack of invasion to adjacent structures, and smaller regional lymph nodes (less than 8 mm) further distinguish XGC from GBC. Despite the reasonable diagnostic performance of CT, with sensitivity and specificity around 75%, the study also highlights the potential for misclassification. These findings emphasize the importance of integrating comprehensive radiological assessments to improve preoperative differentiation, thereby guiding appropriate surgical interventions and enhancing patient outcomes. Further research with larger sample sizes and multi-center collaboration is essential to enhance diagnostic accuracy and develop more robust criteria for differentiating XGC from GBC.</p></sec></body><back><fn-group><fn id="n1" fn-type="COI-statement"><p>
<bold>Competing Interests</bold>
</p><p> The authors declare that they have no competing interests.</p></fn><fn id="n2" fn-type="other"><p>
<bold>Ethical Approval</bold>
</p><p> The procedure followed institutional ethics and complied with the WMA Declaration of Helsinki for medical research involving human subjects (approval number: 2023/196, dated 15.11.2023).</p></fn><fn id="n3" fn-type="financial-disclosure"><p>
<bold>Funding</bold>
</p><p> No funding was obtained for this study.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Truant</surname><given-names>S</given-names></name>
<name><surname>Chater</surname><given-names>C</given-names></name>
<name><surname>Pruvot</surname><given-names>FR</given-names></name>
</person-group><article-title>Greatly enlarged thickened gallbladder Diagnosis: xanthogranulomatous cholecystitis (XGC)</article-title><source>JAMA Surg</source><year>2015</year><volume>150</volume><issue>3</issue><fpage>267</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2014.492</pub-id><pub-id pub-id-type="pmid">25565381</pub-id>
</element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>H</given-names></name>
<name><surname>Wada</surname><given-names>S</given-names></name>
<name><surname>Araki</surname><given-names>K</given-names></name>
<name><surname>Kubo</surname><given-names>N</given-names></name>
<name><surname>Watanabe</surname><given-names>A</given-names></name>
<name><surname>Tsukagoshi</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Xanthogranulomatous cholecystitis: difficulty in differentiating from gallbladder cancer</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><issue>35</issue><fpage>10166</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i35.10166</pub-id><pub-id pub-id-type="pmid">26401081</pub-id>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>VP</given-names></name>
<name><surname>Rajesh</surname><given-names>S</given-names></name>
<name><surname>Bihari</surname><given-names>C</given-names></name>
<name><surname>Desai</surname><given-names>SN</given-names></name>
<name><surname>Pargewar</surname><given-names>SS</given-names></name>
<name><surname>Arora</surname><given-names>A</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: what every radiologist should know</article-title><source>World J Radiol</source><year>2016</year><volume>8</volume><issue>2</issue><fpage>183</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.4329/wjr.v8.i2.183</pub-id><pub-id pub-id-type="pmid">26981227</pub-id>
</element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bray</surname><given-names>F</given-names></name>
<name><surname>Ferlay</surname><given-names>J</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I</given-names></name>
<name><surname>Siegel</surname><given-names>RL</given-names></name>
<name><surname>Torre</surname><given-names>LA</given-names></name>
<name><surname>Jemal</surname><given-names>A</given-names></name>
</person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>6</issue><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id>
</element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>H</given-names></name>
<name><surname>Yu</surname><given-names>TN</given-names></name>
<name><surname>Cai</surname><given-names>XJ</given-names></name>
</person-group><article-title>Tumor biomarkers: help or mislead in the diagnosis of xanthogranulomatous cholecystitis?-Analysis of serum CA 19-9, carcinoembryonic antigen, and CA 12-5</article-title><source>Chin Med J (Engl)</source><year>2013</year><volume>126</volume><issue>16</issue><fpage>3044</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23981609</pub-id>
</element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mann</surname><given-names>DV</given-names></name>
<name><surname>Edwards</surname><given-names>R</given-names></name>
<name><surname>Ho</surname><given-names>S</given-names></name>
<name><surname>Lau</surname><given-names>WY</given-names></name>
<name><surname>Glazer</surname><given-names>G</given-names></name>
</person-group><article-title>Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice</article-title><source>Eur J Surg Oncol</source><year>2000</year><volume>26</volume><issue>5</issue><fpage>474</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/ejso.1999.0925</pub-id><pub-id pub-id-type="pmid">11016469</pub-id>
</element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>TW</given-names></name>
<name><surname>Kim</surname><given-names>SH</given-names></name>
<name><surname>Park</surname><given-names>HJ</given-names></name>
<name><surname>Lim</surname><given-names>S</given-names></name>
<name><surname>Jang</surname><given-names>KM</given-names></name>
<name><surname>Choi</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>Differentiating xanthogranulomatous cholecystitis from wall-thickening type of gallbladder cancer: added value of diffusion-weighted MRI</article-title><source>Clin Radiol</source><year>2013</year><volume>68</volume><issue>10</issue><fpage>992</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2013.03.022</pub-id><pub-id pub-id-type="pmid">23622795</pub-id>
</element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalage</surname><given-names>D</given-names></name>
<name><surname>Gupta</surname><given-names>P</given-names></name>
<name><surname>Gulati</surname><given-names>A</given-names></name>
<name><surname>Yadav</surname><given-names>TD</given-names></name>
<name><surname>Gupta</surname><given-names>V</given-names></name>
<name><surname>Kaman</surname><given-names>L</given-names></name>
<etal/>
</person-group><article-title>Multiparametric MR imaging with diffusion-weighted, intravoxel incoherent motion, diffusion tensor, and dynamic contrast-enhanced perfusion sequences to assess gallbladder wall thickening: a prospective study based on surgical histopathology</article-title><source>Eur Radiol</source><year>2023</year><volume>33</volume><issue>7</issue><fpage>4981</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/s00330-023-09455-w</pub-id><pub-id pub-id-type="pmid">36826499</pub-id>
</element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>HX</given-names></name>
<name><surname>Wang</surname><given-names>WP</given-names></name>
<name><surname>Wen</surname><given-names>JX</given-names></name>
<name><surname>Ji</surname><given-names>ZB</given-names></name>
<name><surname>Ding</surname><given-names>H</given-names></name>
<name><surname>Huang</surname><given-names>BJ</given-names></name>
<etal/>
</person-group><article-title>Xanthogranulomatous cholecystitis: contrast-enhanced ultrasound features and differential diagnosis from wall-thickening gallbladder carcinoma</article-title><source>Discov Med</source><year>2016</year><volume>21</volume><issue>114</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">27011044</pub-id>
</element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>ES</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
<name><surname>Joo</surname><given-names>I</given-names></name>
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Han</surname><given-names>JK</given-names></name>
<name><surname>Choi</surname><given-names>BI</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: diagnostic performance of US, CT, and MRI for differentiation from gallbladder carcinoma</article-title><source>Abdom Imaging</source><year>2015</year><volume>40</volume><issue>7</issue><fpage>2281</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s00261-015-0432-x</pub-id><pub-id pub-id-type="pmid">25952571</pub-id>
</element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bo</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>E</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Nan</surname><given-names>L</given-names></name>
<name><surname>Xin</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Diagnostic accuracy of imaging modalities in differentiating xanthogranulomatous cholecystitis from gallbladder cancer</article-title><source>Ann Transl Med</source><year>2019</year><volume>7</volume><issue>22</issue><fpage>627</fpage><pub-id pub-id-type="doi">10.21037/atm.2019.11.35</pub-id><pub-id pub-id-type="pmid">31930028</pub-id>
</element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabat&#x000e9;-Llobera</surname><given-names>A</given-names></name>
<name><surname>Reyn&#x000e9;s-Llompart</surname><given-names>G</given-names></name>
<name><surname>Mestres-Mart&#x000ed;</surname><given-names>J</given-names></name>
<name><surname>Gr&#x000e0;cia-S&#x000e1;nchez</surname><given-names>L</given-names></name>
<name><surname>Llad&#x000f3;</surname><given-names>L</given-names></name>
<name><surname>Serrano</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Imaging gallbladder lesions: what can positron emission tomography/computed tomography add to the conventional imaging approach?</article-title><source>J Comput Assist Tomogr</source><year>2023</year><volume>47</volume><issue>3</issue><fpage>343</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/rct.0000000000001431</pub-id><pub-id pub-id-type="pmid">37184994</pub-id>
</element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishnani</surname><given-names>N</given-names></name>
<name><surname>Dhingra</surname><given-names>S</given-names></name>
<name><surname>Kapoor</surname><given-names>S</given-names></name>
<name><surname>Pandey</surname><given-names>R</given-names></name>
</person-group><article-title>Cytopathologic diagnosis of xanthogranulomatous cholecystitis and coexistent lesions A prospective study of 31 cases</article-title><source>Acta Cytol</source><year>2007</year><volume>51</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000325680</pub-id><pub-id pub-id-type="pmid">17328493</pub-id>
</element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>RV</given-names></name>
<name><surname>Kumar</surname><given-names>A</given-names></name>
<name><surname>Sikora</surname><given-names>SS</given-names></name>
<name><surname>Saxena</surname><given-names>R</given-names></name>
<name><surname>Kapoor</surname><given-names>VK</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: differentiation from associated gall bladder carcinoma</article-title><source>Trop Gastroenterol</source><year>2005</year><volume>26</volume><issue>1</issue><fpage>31</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15974235</pub-id>
</element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rana</surname><given-names>C</given-names></name>
<name><surname>Krishnani</surname><given-names>N</given-names></name>
<name><surname>Kumari</surname><given-names>N</given-names></name>
</person-group><article-title>Ultrasound-guided fine needle aspiration cytology of gallbladder lesions: a study of 596 cases</article-title><source>Cytopathology</source><year>2016</year><volume>27</volume><issue>6</issue><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1111/cyt.12296</pub-id><pub-id pub-id-type="pmid">26990137</pub-id>
</element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>J</given-names></name>
<name><surname>Zhou</surname><given-names>R</given-names></name>
<name><surname>Zhang</surname><given-names>B</given-names></name>
<name><surname>Li</surname><given-names>B</given-names></name>
</person-group><article-title>Noninvasive preoperative differential diagnosis of gallbladder carcinoma and xanthogranulomatous cholecystitis: a retrospective cohort study of 240 patients</article-title><source>Cancer Med</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>176</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/cam4.4442</pub-id><pub-id pub-id-type="pmid">34837350</pub-id>
</element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spinelli</surname><given-names>A</given-names></name>
<name><surname>Schumacher</surname><given-names>G</given-names></name>
<name><surname>Pascher</surname><given-names>A</given-names></name>
<name><surname>Lopez-Hanninen</surname><given-names>E</given-names></name>
<name><surname>Al-Abadi</surname><given-names>H</given-names></name>
<name><surname>Benckert</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Extended surgical resection for xanthogranulomatous cholecystitis mimicking advanced gallbladder carcinoma: a case report and review of literature</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><issue>14</issue><fpage>2293</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3748/wjg.v12.i14.2293</pub-id><pub-id pub-id-type="pmid">16610041</pub-id>
</element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rawla</surname><given-names>P</given-names></name>
<name><surname>Sunkara</surname><given-names>T</given-names></name>
<name><surname>Thandra</surname><given-names>KC</given-names></name>
<name><surname>Barsouk</surname><given-names>A</given-names></name>
</person-group><article-title>Epidemiology of gallbladder cancer</article-title><source>Clin Exp Hepatol</source><year>2019</year><volume>5</volume><issue>2</issue><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.5114/ceh.2019.85166</pub-id><pub-id pub-id-type="pmid">31501784</pub-id>
</element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ito</surname><given-names>R</given-names></name>
<name><surname>Kobayashi</surname><given-names>T</given-names></name>
<name><surname>Ogasawara</surname><given-names>G</given-names></name>
<name><surname>Kono</surname><given-names>Y</given-names></name>
<name><surname>Mori</surname><given-names>K</given-names></name>
<name><surname>Kawasaki</surname><given-names>S</given-names></name>
</person-group><article-title>A scoring system based on computed tomography for the correct diagnosis of xanthogranulomatous cholecystitis</article-title><source>Acta Radiol Open</source><year>2020</year><volume>9</volume><issue>4</issue><fpage>2058460120918237</fpage><pub-id pub-id-type="doi">10.1177/2058460120918237</pub-id><pub-id pub-id-type="pmid">32313694</pub-id>
</element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dincer</surname><given-names>HA</given-names></name>
<name><surname>Cennet</surname><given-names>O</given-names></name>
<name><surname>Dogrul</surname><given-names>AB</given-names></name>
</person-group><article-title>The utility of systemic immune inflammatory index in discriminating between gallbladder cancer and xanthogranulomatous cholecystitis: a single-tertiary center experience</article-title><source>Medicine (Baltimore)</source><year>2023</year><volume>102</volume><issue>43</issue><fpage>e35805</fpage><pub-id pub-id-type="doi">10.1097/md.0000000000035805</pub-id><pub-id pub-id-type="pmid">37904388</pub-id>
</element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajaguru</surname><given-names>K</given-names></name>
<name><surname>Mehrotra</surname><given-names>S</given-names></name>
<name><surname>Lalwani</surname><given-names>S</given-names></name>
<name><surname>Mangla</surname><given-names>V</given-names></name>
<name><surname>Mehta</surname><given-names>N</given-names></name>
<name><surname>Nundy</surname><given-names>S</given-names></name>
</person-group><article-title>New scoring system for differentiating xanthogranulomatous cholecystitis from gall bladder carcinoma: a tertiary care centre experience</article-title><source>ANZ J Surg</source><year>2018</year><volume>88</volume><issue>1-2</issue><fpage>E34</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/ans.13733</pub-id><pub-id pub-id-type="pmid">27599003</pub-id>
</element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kishore</surname><given-names>R</given-names></name>
<name><surname>Nundy</surname><given-names>S</given-names></name>
<name><surname>Mehrotra</surname><given-names>S</given-names></name>
<name><surname>Metha</surname><given-names>N</given-names></name>
<name><surname>Mangla</surname><given-names>V</given-names></name>
<name><surname>Lalwani</surname><given-names>S</given-names></name>
</person-group><article-title>Strategies for differentiating gallbladder carcinoma from xanthogranulomatous cholecystitis-a tertiary care centre experience</article-title><source>Indian J Surg Oncol</source><year>2017</year><volume>8</volume><issue>4</issue><fpage>554</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s13193-017-0677-7</pub-id><pub-id pub-id-type="pmid">29203989</pub-id>
</element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goshima</surname><given-names>S</given-names></name>
<name><surname>Chang</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>JH</given-names></name>
<name><surname>Kanematsu</surname><given-names>M</given-names></name>
<name><surname>Bae</surname><given-names>KT</given-names></name>
<name><surname>Federle</surname><given-names>MP</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: diagnostic performance of CT to differentiate from gallbladder cancer</article-title><source>Eur J Radiol</source><year>2010</year><volume>74</volume><issue>3</issue><fpage>e79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2009.04.017</pub-id><pub-id pub-id-type="pmid">19446416</pub-id>
</element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frountzas</surname><given-names>M</given-names></name>
<name><surname>Schizas</surname><given-names>D</given-names></name>
<name><surname>Liatsou</surname><given-names>E</given-names></name>
<name><surname>Economopoulos</surname><given-names>KP</given-names></name>
<name><surname>Nikolaou</surname><given-names>C</given-names></name>
<name><surname>Apostolou</surname><given-names>KG</given-names></name>
<etal/>
</person-group><article-title>Presentation and surgical management of xanthogranulomatous cholecystitis</article-title><source>Hepatobiliary Pancreat Dis Int</source><year>2021</year><volume>20</volume><issue>2</issue><fpage>117</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.hbpd.2021.01.002</pub-id><pub-id pub-id-type="pmid">33536138</pub-id>
</element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giudicelli</surname><given-names>X</given-names></name>
<name><surname>Rode</surname><given-names>A</given-names></name>
<name><surname>Bancel</surname><given-names>B</given-names></name>
<name><surname>Nguyen</surname><given-names>AT</given-names></name>
<name><surname>Mabrut</surname><given-names>JY</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: diagnosis and management</article-title><source>J Visc Surg</source><year>2021</year><volume>158</volume><issue>4</issue><fpage>326</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.jviscsurg.2021.02.004</pub-id><pub-id pub-id-type="pmid">33741306</pub-id>
</element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wasnik</surname><given-names>AP</given-names></name>
<name><surname>Davenport</surname><given-names>MS</given-names></name>
<name><surname>Kaza</surname><given-names>RK</given-names></name>
<name><surname>Weadock</surname><given-names>WJ</given-names></name>
<name><surname>Udager</surname><given-names>A</given-names></name>
<name><surname>Keshavarzi</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis</article-title><source>Clin Imaging</source><year>2018</year><volume>50</volume><fpage>223</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.clinimag.2018.04.010</pub-id><pub-id pub-id-type="pmid">29679780</pub-id>
</element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>L</given-names></name>
<name><surname>You</surname><given-names>Z</given-names></name>
<name><surname>Gou</surname><given-names>J</given-names></name>
<name><surname>Liao</surname><given-names>E</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: experience in 100 cases</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><issue>17</issue><fpage>1089</fpage><pub-id pub-id-type="doi">10.21037/atm-20-5836</pub-id><pub-id pub-id-type="pmid">33145308</pub-id>
</element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Song</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>S</given-names></name>
</person-group><article-title>Progress in gallbladder cancer with lymph node metastasis</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>966835</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.966835</pub-id><pub-id pub-id-type="pmid">36072797</pub-id>
</element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramachandran</surname><given-names>A</given-names></name>
<name><surname>Srivastava</surname><given-names>DN</given-names></name>
<name><surname>Madhusudhan</surname><given-names>KS</given-names></name>
</person-group><article-title>Gallbladder cancer revisited: the evolving role of a radiologist</article-title><source>Br J Radiol</source><year>2021</year><volume>94</volume><issue>1117</issue><fpage>20200726</fpage><pub-id pub-id-type="doi">10.1259/bjr.20200726</pub-id><pub-id pub-id-type="pmid">33090880</pub-id>
</element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopes Vendrami</surname><given-names>C</given-names></name>
<name><surname>Magnetta</surname><given-names>MJ</given-names></name>
<name><surname>Mittal</surname><given-names>PK</given-names></name>
<name><surname>Moreno</surname><given-names>CC</given-names></name>
<name><surname>Miller</surname><given-names>FH</given-names></name>
</person-group><article-title>Gallbladder carcinoma and its differential diagnosis at MRI: what radiologists should know</article-title><source>Radiographics</source><year>2021</year><volume>41</volume><issue>1</issue><fpage>78</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1148/rg.2021200087</pub-id><pub-id pub-id-type="pmid">33306452</pub-id>
</element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>S</given-names></name>
<name><surname>Lee</surname><given-names>YH</given-names></name>
<name><surname>Kim</surname><given-names>YR</given-names></name>
<name><surname>Soh</surname><given-names>EG</given-names></name>
</person-group><article-title>Usefulness of MRI scoring system for differential diagnosis between xanthogranulomatous cholecystitis and wall-thickening type gallbladder cancer</article-title><source>J Korean Soc Radiol</source><year>2024</year><volume>85</volume><issue>1</issue><fpage>147</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3348/jksr.2023.0036</pub-id><pub-id pub-id-type="pmid">38362397</pub-id>
</element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatakenaka</surname><given-names>M</given-names></name>
<name><surname>Adachi</surname><given-names>T</given-names></name>
<name><surname>Matsuyama</surname><given-names>A</given-names></name>
<name><surname>Mori</surname><given-names>M</given-names></name>
<name><surname>Yoshikawa</surname><given-names>Y</given-names></name>
</person-group><article-title>Xanthogranulomatous cholecystitis: importance of chemical-shift gradient-echo MR imaging</article-title><source>Eur Radiol</source><year>2003</year><volume>13</volume><issue>9</issue><fpage>2233</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s00330-002-1731-5</pub-id><pub-id pub-id-type="pmid">12928971</pub-id>
</element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>F</given-names></name>
<name><surname>Lu</surname><given-names>PX</given-names></name>
<name><surname>Yan</surname><given-names>SX</given-names></name>
<name><surname>Wang</surname><given-names>GF</given-names></name>
<name><surname>Yuan</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>SZ</given-names></name>
<etal/>
</person-group><article-title>CT and MR features of xanthogranulomatous cholecystitis: an analysis of consecutive 49 cases</article-title><source>Eur J Radiol</source><year>2013</year><volume>82</volume><issue>9</issue><fpage>1391</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2013.04.026</pub-id><pub-id pub-id-type="pmid">23726123</pub-id>
</element-citation></ref></ref-list></back></article>